Hide metadata

dc.date.accessioned2023-08-18T15:47:50Z
dc.date.available2023-08-18T15:47:50Z
dc.date.created2023-01-21T18:08:11Z
dc.date.issued2023
dc.identifier.citationRoman, Giacomo Stavik, Benedicte Lauritzen, Knut Husø Sandset, Per Morten Harrison, Sean Sullivan, Gareth John Chollet, Maria Eugenia . “iPSC-derived liver organoids and inherited bleeding disorders: Potential and future perspectives”. Frontiers in Physiology. 2023, 14
dc.identifier.urihttp://hdl.handle.net/10852/103396
dc.description.abstractThe bleeding phenotype of hereditary coagulation disorders is caused by the low or undetectable activity of the proteins involved in hemostasis, due to a broad spectrum of genetic alterations. Most of the affected coagulation factors are produced in the liver. Therefore, two-dimensional (2D) cultures of primary human hepatocytes and recombinant overexpression of the factors in non-human cell lines have been primarily used to mimic disease pathogenesis and as a model for innovative therapeutic strategies. However, neither human nor animal cells fully represent the hepatocellular biology and do not harbor the exact genetic background of the patient. As a result, the inability of the current in vitro models in recapitulating the in vivo situation has limited the studies of these inherited coagulation disorders. Induced Pluripotent Stem Cell (iPSC) technology offers a possible solution to overcome these limitations by reprogramming patient somatic cells into an embryonic-like pluripotent state, thus giving the possibility of generating an unlimited number of liver cells needed for modeling or therapeutic purposes. By combining this potential and the recent advances in the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 technology, it allows for the generation of autologous and gene corrected liver cells in the form of three-dimensional (3D) liver organoids. The organoids recapitulate cellular composition and organization of the liver, providing a more physiological model to study the biology of coagulation proteins and modeling hereditary coagulation disorders. This advanced methodology can pave the way for the development of cell-based therapeutic approaches to treat inherited coagulation disorders. In this review we will explore the use of liver organoids as a state-of-the-art methodology for modeling coagulation factors disorders and the possibilities of using organoid technology to treat the disease.
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.title“iPSC-derived liver organoids and inherited bleeding disorders: Potential and future perspectives”
dc.title.alternativeENEngelskEnglish“iPSC-derived liver organoids and inherited bleeding disorders: Potential and future perspectives”
dc.typeJournal article
dc.creator.authorRoman, Giacomo
dc.creator.authorStavik, Benedicte
dc.creator.authorLauritzen, Knut Husø
dc.creator.authorSandset, Per Morten
dc.creator.authorHarrison, Sean
dc.creator.authorSullivan, Gareth John
dc.creator.authorChollet, Maria Eugenia
cristin.unitcode185,53,49,11
cristin.unitnameAvdeling for blodsykdommer
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin2112540
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers in Physiology&rft.volume=14&rft.spage=&rft.date=2023
dc.identifier.jtitleFrontiers in Physiology
dc.identifier.volume14
dc.identifier.doihttps://doi.org/10.3389/fphys.2023.1094249
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn1664-042X
dc.type.versionPublishedVersion
cristin.articleid194249
dc.relation.projectHSØ/2019071
dc.relation.projectNFR/325869


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International